For more information, visit Basuch.com Important Risk Information Prescribing Information Visit Zirgan's website

Case #5 - Acute Herpes Simplex Epithelial Keratitis

A 68-year-old female presents with a painful, red eye, linear lesion on the cornea, and a history of inflammation and discomfort attributed to an HSV dendrite. The patient was referred to Dr. Paul Karpecki who prescribed topical Zirgan® antiviral ophthalmic gel. Dr. Karpecki shares the details of his first clinical case with Zirgan gel.

  • Bookmark
  • QuickLink

Indication ZIRGAN® is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Risk Information about ZIRGAN®

  • ZIRGAN® is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Please see the full prescribing information for ZIRGAN® here.

For more information about treating herpes simplex epithelial keratitis with ZIRGAN®, click here.

ZIRGAN is a registered trademark of Laboratoires Théa Corporation licensed by Bausch & Lomb Incorporated.

©2012 Bausch & Lomb Incorporated.
PH4251 2/12

Comments (0)